Antibiotic susceptibility testing (AST) technology firm Avails Medical has announced that it has signed its first US commercial customer, a world renowned academic medical centre and flagship hospital for a six-hospital system, for the company's eQUANT system.
The eQUANT system will support this hospital system's efforts to deliver timely results to providers, enabling appropriate management of sepsis patients and improving patient outcomes.
The eQUANT system is a game-changer in the global effort to combat antibiotic resistance and improve outcomes for sepsis patients. It delivers a standardised inoculum (0.5 McFarland equivalent) directly from positive blood cultures in approximately 70 minutes. By shortening the routine AST turnaround time by up to 24 hours, eQUANT enables faster, targeted therapy and boosts laboratory efficiency. Featuring a compact design, user-friendly interface, and cost-effective system, it integrates seamlessly into existing laboratory workflows and supports widespread adoption across a variety hospital settings.
Oren Knopfmacher PhD, Co-Founder and CEO of Avails Medical said: "I am so proud of the Avails team for this accomplishment and installing the first eQUANT systems at such a prestigious institution. It truly is a testament to how novel and impactful eQUANT is in speeding up the time to actionable results for the sickest patients."